Finerenone improves outcomes in chronic kidney disease with diabetes

Reuters Health - 23/10/2020 - In patients with chronic kidney disease (CKD) and type-2 diabetes, treatment with the investigational drug finerenone protects against CKD progression and cardiovascular events, according to results of a randomized controlled trial. "This is an exciting discovery because we have had many other failed discoveries in this high-risk population of diabetes and chronic kidney disease," Dr. Rajiv Agarwal of Indiana University, in Indianapolis, said in a press briefing. He presented the study results during KidneyWeek, hosted by the American Society of Nephrology (ASN). The results were simultaneously published in The New England Journal of Medicine. Overactivation of the mineralocorticoid receptor is thought to play a role in cardiorenal diseases, including CKD and diabetes, through inflammation and fibrosis that lead to progressive kidney and cardiovascular dysfunction, the authors explain in their paper. Finerenone is a nonste...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 23 October, 202028 October, 2020